MX388733B - Polvos secos antifungicos. - Google Patents

Polvos secos antifungicos.

Info

Publication number
MX388733B
MX388733B MX2019004322A MX2019004322A MX388733B MX 388733 B MX388733 B MX 388733B MX 2019004322 A MX2019004322 A MX 2019004322A MX 2019004322 A MX2019004322 A MX 2019004322A MX 388733 B MX388733 B MX 388733B
Authority
MX
Mexico
Prior art keywords
dry powders
antifungal
antifungal dry
excipients
stabilizer
Prior art date
Application number
MX2019004322A
Other languages
English (en)
Spanish (es)
Other versions
MX2019004322A (es
Inventor
Andrew Emmet O'connor
David L Hava
Hillary S Tracy
Jason M Perry
Jean C Sung
Robert Clifford Saunders
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of MX2019004322A publication Critical patent/MX2019004322A/es
Publication of MX388733B publication Critical patent/MX388733B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2019004322A 2016-10-14 2017-10-13 Polvos secos antifungicos. MX388733B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408376P 2016-10-14 2016-10-14
PCT/US2017/056497 WO2018071757A1 (en) 2016-10-14 2017-10-13 Antifungal dry powders

Publications (2)

Publication Number Publication Date
MX2019004322A MX2019004322A (es) 2019-12-11
MX388733B true MX388733B (es) 2025-03-20

Family

ID=60186406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004322A MX388733B (es) 2016-10-14 2017-10-13 Polvos secos antifungicos.

Country Status (11)

Country Link
US (3) US11116722B2 (enExample)
EP (1) EP3525759A1 (enExample)
JP (1) JP7085538B2 (enExample)
KR (1) KR102408798B1 (enExample)
CN (1) CN109996536B (enExample)
AU (1) AU2017341815B2 (enExample)
IL (1) IL265913B2 (enExample)
MX (1) MX388733B (enExample)
NZ (1) NZ752353A (enExample)
RU (1) RU2766086C2 (enExample)
WO (1) WO2018071757A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4008326A1 (en) * 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
WO2019204583A1 (en) * 2018-04-18 2019-10-24 Pulmatrix Operating Company, Inc. Antifungal formulations for pulmonary administration comprising itraconazole
KR20210014629A (ko) * 2018-04-18 2021-02-09 시플라 테크놀로지스 엘엘씨 진균 감염의 치료방법
WO2021092349A1 (en) * 2019-11-08 2021-05-14 Scynexis, Inc. Lipid-based formulations of scy-078 salts
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
IT202000030437A1 (it) 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
IT202000030443A1 (it) 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
WO2022187222A1 (en) * 2021-03-03 2022-09-09 Pulmatrix Operating Company, Inc. Dihydroergotamine dry power formulations and methods of use
US20260158005A1 (en) * 2021-11-09 2026-06-11 Agency For Science, Technology And Research A salt-based antifungal powder platform formulation for aerosolization
US20250049717A1 (en) * 2021-12-20 2025-02-13 Pulmatrix Operating Company, Inc. Dry powder formulations of narrow spectrum kinase inhibitors
AU2023288123A1 (en) 2022-06-21 2025-01-16 Hovione Scientia Limited Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
EP4580632A2 (en) 2022-08-31 2025-07-09 Pulmatrix Operating Company, Inc. Methods of using itraconazole dry powders
EP4780464A1 (en) * 2023-09-20 2026-07-29 The Board Of Trustees Of The University Of Illinois Use of a dry powder inhaler to treat or prevent pulmonary fungal infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4097620A (en) 1977-05-02 1978-06-27 Xerox Corporation Magnetic toner particle coating process
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US7473433B2 (en) * 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
CA2511555A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
WO2005009375A2 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2007092088A1 (en) 2005-12-28 2007-08-16 Nektar Therapeutics Compositions comprising amphotericin b
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
RU2413506C2 (ru) 2006-08-11 2011-03-10 Панацея Биотек Лимитед Частицы для доставки активных ингредиентов, способ их получения и композиции из них
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
EP2252275B1 (en) 2008-02-13 2017-11-29 Board of Regents, The University of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
EP2095816A1 (en) 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
IN2012DE00674A (enExample) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
WO2014106727A1 (en) 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
KR20150135328A (ko) * 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
CN104398497B (zh) * 2014-10-29 2017-11-24 中山大学 伊曲康唑吸入粉雾剂及其制备方法
CA2972826C (en) * 2015-01-14 2023-09-12 Respira Therapeutics, Inc. Powder dispersion methods and devices
WO2018195086A1 (en) 2017-04-17 2018-10-25 Respira Therapeutics, Inc. Powder dispersion devices and methods

Also Published As

Publication number Publication date
RU2766086C2 (ru) 2022-02-07
RU2019114112A3 (enExample) 2021-02-12
MX2019004322A (es) 2019-12-11
KR20190068591A (ko) 2019-06-18
IL265913B1 (en) 2024-03-01
KR102408798B1 (ko) 2022-06-13
CA3039485A1 (en) 2018-04-19
US20250221928A1 (en) 2025-07-10
CN109996536A (zh) 2019-07-09
AU2017341815A1 (en) 2019-05-02
AU2017341815B2 (en) 2023-06-15
IL265913B2 (en) 2024-07-01
JP7085538B2 (ja) 2022-06-16
NZ752353A (en) 2023-06-30
WO2018071757A1 (en) 2018-04-19
EP3525759A1 (en) 2019-08-21
US11116722B2 (en) 2021-09-14
US20240285523A1 (en) 2024-08-29
JP2019534270A (ja) 2019-11-28
US20200129428A1 (en) 2020-04-30
CN109996536B (zh) 2023-03-07
RU2019114112A (ru) 2020-11-16
IL265913A (en) 2019-06-30
BR112019007459A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
NZ752353A (en) Antifungal dry powders
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
IL274297A (en) Pyrazolo-piperidine-converted indole-2-carboxamides, preparations containing them and their uses
MX2020006595A (es) Oxadiazoles fungicidas.
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
IL300869B2 (en) Ligands containing a targeting factor, compositions containing them and uses thereof
IL263355A (en) Nicotine particles and preparations
FR3052453B1 (fr) Peptide, composition le comprenant et utilisations notamment cosmetiques
IL265770A (en) Conjugates are intended for sstr and particles and their formulations
SG11202103137WA (en) Stable semaglutide compositions and uses thereof
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
SG11202105540YA (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
IL282428A (en) History of pyridinyl sulfonamide, pharmaceutical preparations and their uses
IL272055A (en) 8,1-naphthyridinone compounds and their uses
IL268959A (en) Antibodies with cystine mutation, preparations containing them and their uses
FR3029915B1 (fr) Tripeptides, compositions les comprenant et utilisations notamment cosmetiques
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
SI3654938T1 (sl) Praškaste trdne disperzije, ki obsegajo kvercetin, postopek za njihovo pripravo in formulacije le-teh
GB202002129D0 (en) stable freshening compositions and products comprising the same
SG11202002422WA (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
EP3400214C0 (en) COMPOSITIONS OF 7-AZONIABICYCLO [2.2.1]HEPTANE DERIVATIVES FOR DRY POWDER INHALERS
CL2018002542A1 (es) Na2-imp deshidratada como agente antiaglomerante
MX2020003513A (es) Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos.